全文获取类型
收费全文 | 9096篇 |
免费 | 576篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 355篇 |
妇产科学 | 116篇 |
基础医学 | 1118篇 |
口腔科学 | 115篇 |
临床医学 | 927篇 |
内科学 | 1456篇 |
皮肤病学 | 283篇 |
神经病学 | 885篇 |
特种医学 | 374篇 |
外科学 | 1157篇 |
综合类 | 107篇 |
一般理论 | 12篇 |
预防医学 | 843篇 |
眼科学 | 555篇 |
药学 | 660篇 |
中国医学 | 12篇 |
肿瘤学 | 598篇 |
出版年
2022年 | 32篇 |
2021年 | 109篇 |
2020年 | 83篇 |
2019年 | 131篇 |
2018年 | 151篇 |
2017年 | 119篇 |
2016年 | 114篇 |
2015年 | 167篇 |
2014年 | 258篇 |
2013年 | 408篇 |
2012年 | 515篇 |
2011年 | 619篇 |
2010年 | 318篇 |
2009年 | 252篇 |
2008年 | 525篇 |
2007年 | 577篇 |
2006年 | 537篇 |
2005年 | 578篇 |
2004年 | 561篇 |
2003年 | 510篇 |
2002年 | 543篇 |
2001年 | 128篇 |
2000年 | 119篇 |
1999年 | 97篇 |
1998年 | 83篇 |
1997年 | 62篇 |
1996年 | 54篇 |
1995年 | 87篇 |
1994年 | 67篇 |
1993年 | 74篇 |
1992年 | 98篇 |
1991年 | 104篇 |
1990年 | 107篇 |
1989年 | 78篇 |
1988年 | 71篇 |
1987年 | 66篇 |
1986年 | 81篇 |
1985年 | 85篇 |
1984年 | 95篇 |
1983年 | 98篇 |
1982年 | 104篇 |
1981年 | 91篇 |
1980年 | 84篇 |
1979年 | 57篇 |
1978年 | 63篇 |
1977年 | 63篇 |
1976年 | 52篇 |
1975年 | 44篇 |
1974年 | 52篇 |
1973年 | 39篇 |
排序方式: 共有9693条查询结果,搜索用时 15 毫秒
1.
Chenguang Duan Yuling Jiao Yanming Lai Dingwei Li Xiliang Lu & Jerry Zhijian Yang 《Communications In Computational Physics》2022,31(4):1020-1048
Using deep neural networks to solve PDEs has attracted a lot of attentions
recently. However, why the deep learning method works is falling far behind its empirical success. In this paper, we provide a rigorous numerical analysis on deep Ritz
method (DRM) [47] for second order elliptic equations with Neumann boundary conditions. We establish the first nonasymptotic convergence rate in $H^1$ norm for DRM
using deep networks with ${\rm ReLU}^2$ activation functions. In addition to providing a
theoretical justification of DRM, our study also shed light on how to set the hyperparameter of depth and width to achieve the desired convergence rate in terms of
number of training samples. Technically, we derive bound on the approximation error
of deep ${\rm ReLU}^2$ network in $C^1$ norm and bound on the Rademacher complexity of the
non-Lipschitz composition of gradient norm and ${\rm ReLU}^2$ network, both of which are of
independent interest. 相似文献
2.
David A. Ganz MD PhD Anita H. Yuan PhD MPH Erich J. Greene PhD Nancy K. Latham PT PhD Katy Araujo MPH Albert L. Siu MD MSPH Jay Magaziner MSHyg PhD Jerry H. Gurwitz MD Albert W. Wu MD MPH Neil B. Alexander MD Robert B. Wallace MD MSc Susan L. Greenspan MD Jeremy Rich DPM Elena Volpi MD PhD Stephen C. Waring DVM PhD Patricia C. Dykes RN PhD MA Fred Ko MD MS Neil M. Resnick MD Siobhan K. McMahon PhD MPH GNP Shehzad Basaria MD Rixin Wang PhD Charles Lu MS Denise Esserman PhD James Dziura PhD Michael E. Miller PhD Thomas G. Travison PhD Peter Peduzzi PhD Shalender Bhasin MB BS David B. Reuben MD Thomas M. Gill MD 《Journal of the American Geriatrics Society》2022,70(11):3221-3229
3.
Lombardo Joseph Ko Kevin Shimada Ayako Nelson Nicolas Wright Christopher Chen Jerry Maity Alisha Ruggiero Marissa L. Richard Scott Papanagnou Dimitrios Mitchell Edith Leader Amy Simone Nicole L. 《Cancer causes & control : CCC》2022,33(4):559-582
Cancer Causes & Control - A disparity exists in cancer screening rates for the Sexual and Gender Minority (SGM) community. We sought to understand the perceptions and baseline knowledge of... 相似文献
4.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
5.
6.
McClelland Shearwood Degnin Catherine Chen Yiyi Watson Gordon A. Jaboin Jerry J. 《Journal of neuro-oncology》2019,141(1):159-166
Journal of Neuro-Oncology - High-volume hospitals are associated with improved outcomes in glioblastoma (GBM). However, the impact of travel burden to high-volume centers is poorly understood. We... 相似文献
7.
8.
Laura L Stafman Mary G Waldrop Adele P Williams Jamie M Aye Jerry E Stewart Elizabeth Mroczek-Musulman Karina J Yoon Kimberly Whelan Elizabeth A Beierle 《Journal of pediatric surgery》2019,54(6):1206-1213
PurposeHepatoblastoma is the most common primary liver cancer of childhood and has few prognostic indicators. We have previously shown that Proviral Integration site for Moloney murine leukemia virus (PIM3) kinase decreased hepatoblastoma tumorigenicity. We sought to determine the effect of PIM3 overexpression on hepatoblastoma cells and whether expression of PIM3 correlated with patient/tumor characteristics or survival.MethodsThe hepatoblastoma cell line, HuH6, and patient-derived xenograft, COA67, were utilized. Viability, proliferation, migration, sphere formation, and tumor growth in mice were assessed in PIM3-overexpressing cells. Immunohistochemistry was performed for PIM3 on patient samples. Correlation between stain score and clinical/pathologic characteristics was assessed.ResultsPIM3 overexpression rescued the anti-proliferative effect observed with PIM3 knockdown. Sphere formation was increased in PIM3 overexpressing cells. Cells with PIM3 overexpression yielded larger tumors than those with empty vector. Seventy-four percent of samples expressed PIM3. There was no statistical difference in patient characteristics between subjects with strong versus weak PIM3 staining, but patients with strong PIM3 staining had decreased survival.ConclusionsPIM3 expression plays a role in hepatoblastoma tumorigenesis. PIM3 was present in the majority of hepatoblastomas and higher PIM3 expression correlated with decreased survival. PIM3 warrants investigation as a therapeutic target and prognostic marker for hepatoblastoma. 相似文献
9.
Julie D. Yeterian Danielle S. Berke Jessica R. Carney Alexandra McIntyre‐Smith Katherine St. Cyr Lisa King Nora K. Kline Andrea Phelps Brett T. Litz 《Journal of traumatic stress》2019,32(3):363-372
In the current paper, we first describe the rationale for and methodology employed by an international research consortium, the Moral Injury Outcome Scale (MIOS) Consortium, the aim of which is to develop and validate a content‐valid measure of moral injury as a multidimensional outcome. The MIOS Consortium comprises researchers and clinicians who work with active duty military service members and veterans in the United States, the United Kingdom, the Netherlands, Australia, and Canada. We describe the multiphase psychometric development process being conducted by the Consortium, which will gather phenomenological data from service members, veterans, and clinicians to operationalize subdomains of impact and to generate content for a new measure of moral injury. Second, to illustrate the methodology being employed by the Consortium in the first phase of measure development, we present a small subset of preliminary results from semistructured interviews and questionnaires conducted with care providers (N = 26) at three of the 10 study sites. The themes derived from these initial preliminary clinician interviews suggest that exposure to potentially morally injurious events is associated with broad psychological/behavioral, social, and spiritual/existential impacts. The early findings also suggest that the outcomes associated with acts of commission or omission and events involving others’ transgressions may overlap. These results will be combined with data derived from other clinicians, service members, and veterans to generate the MIOS. 相似文献